Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Anne Kirstine Hundahl Møller, Karen Damgaard Pedersen, Julie Abildgaard, Bodil Laub Petersen & Gedske Daugaard. (2010) Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncologica 49:4, pages 431-435.
Read now
Read now
Articles from other publishers (12)
Jin Sheng, Hongming Pan & Weidong Han. (2023) Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature. Frontiers in Immunology 14.
Crossref
Crossref
Gerdt Hübner, Alwin Krämer & Stefan Janssen. 2020. Kompendium Internistische Onkologie. Kompendium Internistische Onkologie
1
30
.
Tilmann Bochtler, Harald Löffler & Alwin Krämer. (2018) Diagnosis and management of metastatic neoplasms with unknown primary. Seminars in Diagnostic Pathology 35:3, pages 199-206.
Crossref
Crossref
Tilmann Bochtler & Alwin Krämer. (2017) Systemtherapie prognostisch ungünstiger CUP-SyndromeSystemic therapy of prognostically unfavorable CUP syndrome. Der Onkologe 23:12, pages 1000-1005.
Crossref
Crossref
Xiaozhou Yu, Xiaofeng Li, Xiuyu Song, Dong Dai, Lei Zhu, Yanjia Zhu, Jian Wang, Huiqin Zhao & Wengui Xu. (2016) Advantages and disadvantages of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary. Oncology Letters 12:5, pages 3785-3792.
Crossref
Crossref
James MS WasonAdrian P Mander. (2011) The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected. Statistical Methods in Medical Research 24:6, pages 909-919.
Crossref
Crossref
John D. Hainsworth, Gedske Daugaard, Thierry Lesimple, Gerdt Hübner, F. Anthony Greco, Michael J. Stahl, Christian Meyer Zum Büschenfelde, Djelila Allouache, Nicolas Penel, Poul Knoblauch & Karim S. Fizazi. (2015) Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer 121:10, pages 1654-1661.
Crossref
Crossref
J Lee, S Hahn, D-W Kim, J Kim, S N Kang, S Y Rha, K B Lee, J-H Kang & B-J Park. (2012) Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. British Journal of Cancer 108:1, pages 39-48.
Crossref
Crossref
M. Stahl & B. Brücher-Encke. (2012) CUP – Internistische Therapie bei ungünstigem RisikoprofilCUP – Systemic treatment in patients with unfavourable prognostic factors. Der Onkologe 19:1, pages 29-35.
Crossref
Crossref
Eric Yaovi Amela, Géraldine Lauridant-Philippin, Sophie Cousin, Thomas Ryckewaert, Antoine Adenis & Nicolas Penel. (2012) Management of “unfavourable” carcinoma of unknown primary site: Synthesis of recent literature. Critical Reviews in Oncology/Hematology 84:2, pages 213-223.
Crossref
Crossref
J. Song, D.-X. Zhong, W. Qian, X.-H. Hou & J. D. Z. Chen. (2011) Short pulse gastric electrical stimulation for cisplatin-induced emesis in dogs. Neurogastroenterology & Motility 23:5, pages 468-e178.
Crossref
Crossref
Anne Kirstine Hundahl Moller, Annika Loft, Anne Kiil Berthelsen, Karen Damgaard Pedersen, Jesper Graff, Charlotte Birk Christensen, Katharina Perell, Bodil Laub PetersenGedske Daugaard. (2011) 18F-FDG PET/CT as a Diagnostic Tool in Patients with Extracervical Carcinoma of Unknown Primary Site: A Literature Review. The Oncologist 16:4, pages 445-451.
Crossref
Crossref